We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
(+75,773%)
Cap. Flow
+$169M
Cap. Flow
% of AUM
7.05%
Top 10 Holdings %
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tempest Therapeutics
TPST
|
+$94.4M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$24M |
| 3 |
AGN
Allergan plc
AGN
|
+$13.8M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$11.9M |
| 5 |
MBLY
Mobileye N.V.
MBLY
|
+$8.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$42.1M |
| 2 |
Gilead Sciences
GILD
|
+$11.5M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$11.1M |
| 4 |
Agilent Technologies
A
|
+$6.68M |
| 5 |
ADVM
Adverum Biotechnologies
ADVM
|
+$3.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 9.36% |
| 2 | Technology | 0.55% |
| 3 | Energy | 0.39% |
| 4 | Industrials | 0.16% |
| 5 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $241M | 10.04% |
19,345
+13,851
| +252% | +$1.26M |
|
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $154M | 6.4% |
7,441
-147
| -2% | -$30.3K |
|
3
CALL
Biogen
BIIB
$30.4B
| $131M | 5.45% |
3,102
-1,478
| -32% | -$583K |
|
4
CALL
Merck
MRK
$326B
| $98.8M | 4.11% |
18,013
+16,465
| +1,064% | +$932K |
|
|
5
CALL
Gilead Sciences
GILD
$167B
| $97.8M | 4.07% |
9,967
+9,170
| +1,151% | +$931K |
|
|
SLXP
6
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $78.7M | 3.28% |
4,554
+4,396
| +2,782% | +$645K |
|
7
CALL
Eli Lilly
LLY
$1.09T
| $72.4M | 3.01% |
9,961
+3,556
| +56% | +$253K |
|
8
CALL
Teva Pharmaceuticals
TEVA
$36.9B
| $64.4M | 2.68% |
10,338
+9,922
| +2,385% | +$577K |
|
|
9
CALL
Pfizer
PFE
$144B
| $63.8M | 2.66% |
19,321
+11,092
| +135% | +$353K |
|
10
CALL
Bristol-Myers Squibb
BMY
$130B
| $61.1M | 2.54% |
9,473
-15,290
| -62% | -$957K |
|
11
CALL
AbbVie
ABBV
$465B
| $60.3M | 2.51% |
10,307
-2,485
| -19% | -$150K |
|
12
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
| $49.9M | 2.08% |
1,106
+1,063
| +2,472% | +$451K |
|
|
BLUE
13
CALL
DELISTED
bluebird bio
BLUE
| $36.2M | 1.51% |
231
+125
| +118% | +$165K |
|
|
AGN
14
CALL
DELISTED
Allergan plc
AGN
| $35.9M | 1.49% |
1,205
-1,113
| -48% | -$317K |
|
|
15
PUT
Merck
MRK
$326B
| $34.3M | 1.43% |
6,245
+3,072
| +97% | +$174K |
|
16
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
| $33.9M | 1.41% |
3,249
+2,543
| +360% | +$258K |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $33.8M | 1.41% |
113,566
+48,385
| +74% | +$13.8M |
|
18
PUT
Tenet Healthcare
THC
$22.6B
| $28.5M | 1.19% |
5,752
+4,868
| +551% | +$228K |
|
19
CALL
BioMarin Pharmaceuticals
BMRN
$12B
| $26.9M | 1.12% |
2,161
+1,238
| +134% | +$131K |
|
|
20
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
| $26.1M | 1.09% |
+579
| New | +$245K |
|
|
21
iShares Russell 2000 ETF
IWM
$80.4B
| $24.7M | 1.03% |
+198,690
| New | +$24M |
|
|
ICPT
22
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $23.8M | 0.99% |
+843
| New | +$183K |
|
|
MBLY
23
PUT
DELISTED
Mobileye N.V.
MBLY
| $23.7M | 0.99% |
5,636
+3,578
| +174% | +$139K |
|
|
NVO
24
CALL
Novo Nordisk
NVO
$225B
| $22.5M | 0.94% |
+8,444
| New | +$194K |
|
25
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $22.3M | 0.93% |
1,974
+1,796
| +1,009% | +$90.8K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q1 2015 Portfolio in Review
As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.
By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.
- Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
- Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
- Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
- Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
- Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
- Sabby Management opened 126 new positions and closed 85 in Q1 2015.
- Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.
Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.